Trial Profile

A Single-Dose, Open-Label, Randomized, Two-Way Crossover Study to Assess the Bioequivalence of Tapentadol Given as Two 50-mg Extended-Release, Tamper-Resistant Formulation (TRF) Tablets Relative to One 100-mg Extended-Release TRF Tablet in Healthy Japanese Male Subjects.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 15 Mar 2012

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tapentadol (Primary)
Indications Back pain; Cancer pain; Diabetic neuropathies; Musculoskeletal pain; Neuropathic pain; Pain
Focus Pharmacokinetics

12 Mar 2012 Actual end date changed from Feb 2011 to Mar 2011 as reported by ClinicalTrials.gov.
12 Mar 2012 Actual initiation date changed from Feb 2011 to Dec 2010 as reported by ClinicalTrials.gov.
10 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com